Cosmo Pharmaceuticals Nv Stock Price, News & Analysis

Cosmo Pharmaceuticals has released its Annual Report for fiscal year 2024, following the unaudited results announcement on March 6, 2025. The report highlights a year of strong financial performance and exceptional revenue growth, accompanied by significant strategic advancements.

The Board of Directors has proposed a dividend distribution of €2.05 per share, an increase from €2.00 in the previous year. The Ordinary Annual General Meeting of Shareholders is scheduled for May 30, 2025, with the invitation and proposed resolutions to be available on April 29, 2025.

The company will host an Investor Day in Zurich on July 1, providing an opportunity for engagement with investors, analysts, and media professionals. The comprehensive report includes consolidated and audited financial results, corporate governance details, compensation information, and ESG topics.

Cosmo Pharmaceuticals reported record unaudited results for FY 2024, with revenue reaching €266.8 million, a 188% year-over-year increase. The company achieved an operating profit of €148.9 million and EBITDA of €161.2 million, up 1,517% from previous year.

Key highlights include:

• Cash position increased 239% to €170.4 million with zero debt
• Completed Phase III enrollment for Androgenetic Alopecia treatment in males with 1,495 patients
• GI Genius™ received FDA clearance for Module 300 hardware
• Winlevi® maintains position as #1 branded prescription topical acne treatment in U.S.

For 2025, Cosmo projects total revenues of €102-107 million, with recurring revenues of €85-90 million. The company plans to invest €40 million in R&D and proposes a dividend increase to €2.05 per share.

Cosmo Pharmaceuticals has announced it will host an Investor Day on Wednesday, April 9, 2025, at the Park Hyatt Hotel in Zurich, Switzerland. The event will commence at 11:00am CET, featuring presentations followed by lunch.

The program will include detailed presentations from the Management team covering the company's R&D pipeline, long-term strategic initiatives, and growth opportunities. CEO Giovanni Di Napoli and the executive team will conduct a Q&A session with investors, analysts, and media representatives.

Registration details for in-person attendance and live webcast information will be available in the Events & Presentations section of Cosmo's website. A replay of the webcast will be provided after the event.

Cosmo Pharmaceuticals has appointed Andrea Cherubini as Chief AI Officer, marking a strategic move to integrate AI across its portfolio. Cherubini, who previously served as Senior Vice President - Science, AI, and Data since 2018, was instrumental in developing GI Genius™, the first AI-powered polyp detection system in gastroenterology.

In his new role, Cherubini will expand AI applications beyond endoscopy into multiple areas including:

• Gastroenterology pipeline, focusing on Bile Acid Diarrhea (BAD)
• Dermatology pipeline, optimizing clinical trials for Breezula®
• Drug discovery and development

CEO Giovanni Di Napoli emphasized AI's role as a core growth pillar, while Cherubini expressed commitment to advancing AI-driven healthcare solutions across drug development, diagnostics, and personalized medicine.

Cosmo Pharmaceuticals and Glenmark Pharmaceuticals announced that Glenmark has received MHRA approval to market Winlevi® in the United Kingdom for treating acne vulgaris in patients aged 12 and older. Winlevi® is the first topical acne treatment in nearly 40 years with a novel mechanism of action, featuring clascoterone as its active ingredient.

The treatment is the first commercially available topical androgen receptor inhibitor, targeting sebaceous glands without systemic anti-androgen effects, making it safe for both males and females. Two phase III studies showed that clascoterone cream 1%, applied twice daily for 12 weeks, outperformed vehicle cream in achieving Investigator's Global Assessment success and reducing lesion counts.

This approval stems from a September 2023 agreement where Glenmark in-licensed the product from Cosmo for distribution in Europe and South Africa. The treatment addresses a significant market, as acne affects over 90% of the global population at some point in their lives.

Cosmo Pharmaceuticals (SIX: COPN: C43) has announced it will release its unaudited Full-Year 2024 financial results on March 6, 2025, at 7:00 am CET. The company will host a live webcast presentation at 3:00 pm CET on the same day.

CEO Giovanni Di Napoli and CFO Svetlana Sigalova will present a detailed overview of the company's financial and operational performance, discuss strategic initiatives, growth opportunities, and future outlook. A Q&A session will follow the presentation.

The webcast will be accessible online with replay available for three months. The complete 2024 Annual Report will be published on March 20, 2025, at 7:00 am CET on the company's website.

Cosmo Pharmaceuticals reported strong preliminary unaudited 2024 results with revenue of €265.7 million, representing a 186% increase from €92.8 million in 2023. The growth includes €185 million in non-recurring revenues from Medtronic. Year-end cash position strengthened to €170.4 million from €50.3 million in 2023, with zero debt.

Key pipeline updates include: GI Genius™ received FDA 510(k) clearance for module 300 hardware; Winlevi® became the top-prescribed branded topical acne treatment in the U.S. with over 1.2 million prescriptions since 2021; Breezula® phase III clinical program for androgenetic alopecia progressing with results expected in 2025. Additional programs include Phase II studies for Bile Acid Diarrhea and Distal Ulcerative Colitis, plus a Phase I study for Solid Tumors.

Cosmo Pharmaceuticals (SIX: COPN, FSE: C43) has announced the appointment of Dominika Spilarova as Chief Strategy Officer, effective January 10, 2025. This newly created position will report directly to the CEO. Spilarova brings over 15 years of experience in Life Sciences and management consulting, having previously worked with PwC and running her own Life Sciences consulting business. She has a track record of developing strategies that have impacted businesses with revenues ranging from $26 million to $19.5 billion.

In addition to her CSO role, Spilarova will serve as acting Chief of Staff for the executive leadership team until a permanent appointment is made. The appointment comes as Cosmo reports a strong close for Full Year 2024, with the company focusing on strategy-led growth and innovation.

Cosmo Pharmaceuticals N.V. (SIX: COPN, FSE: C43) shareholders approved the appointment of Deloitte Accountants B.V. as the new independent auditor for the financial year ending December 31, 2024, at an Extraordinary General Meeting (EGM) held on October 18, 2024. This decision follows the Board of Directors' proposal to rotate auditors in line with good governance practices. The previous auditor had been in place since 2016.

The EGM saw a representation of 8,367,544 ordinary shares, constituting 47.70% of Cosmo's total outstanding ordinary shares as of the record date. This change in auditors reflects Cosmo's commitment to maintaining strong corporate governance standards.